Eric Swayze, serving as the Executive Vice President of Research at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), executed a sale of 10,602 shares of the company's common stock on June 25, 2026. The transaction resulted in proceeds totaling $839,491. The shares were divested at a weighted average price of $79.18 per share, with the individual transaction prices ranging between $79.00 and $79.46.
This sale was carried out pursuant to a Rule 10b5-1 trading plan, which Mr. Swayze adopted on March 6, 2026. Following the completion of this transaction, Mr. Swayze's direct holdings in Ionis Pharmaceuticals common stock stand at 21,759 shares. Additionally, he maintains an indirect holding of 318 shares through his son.
The stock has demonstrated significant momentum, surging more than 104% over the past year. At the time of reporting, the stock was trading at $81.18, positioning it near its 52-week high of $86.74. According to InvestingPro analysis, the stock currently appears overvalued based on its Fair Value assessment. Investors seeking deeper insights can access 13 additional ProTips and comprehensive Pro Research Reports for further analysis.
In parallel developments, Ionis Pharmaceuticals has secured approval from the U.S. Food and Drug Administration for its drug Tryngolza (olezarsen). This approval, granted under the Priority Review pathway, permits the drug to be used as an adjunct to diet. The indication focuses on reducing triglycerides and the risk of acute pancreatitis in adults suffering from severe hypertriglyceridemia.
Market analysts have responded positively to this regulatory milestone. Needham has reiterated a Buy rating for the stock, maintaining a price target of $105. H.C. Wainwright has raised its price target to $130, while upholding a Buy rating. Oppenheimer has also upheld its Outperform rating, highlighting Tryngolza as the only therapy capable of significantly reducing triglycerides and lowering the risk of acute pancreatitis.
Furthermore, Ionis Pharmaceuticals has announced the appointment of Ludwig Hantson to its board of directors. Hantson brings over three decades of experience in the biopharmaceutical and medical device sectors. Prior to this appointment, he served as CEO and board member of Alexion. These developments mark significant progress for Ionis Pharmaceuticals in both its product offerings and leadership team.